Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 808-816

  Waldmeier, Felix ^a   Bruin, Gerard J ^a   Glaenzel, Ulrike ^a   Hazell, Katharine ^a   Sechaud, Romain ^a   Warrington, Steve ^b   Porter, John B ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 O GLUCURONIDE; 5 HYDROXY (OH) DEFERASIROX; 5 OH DEFERASIROX; ACYL GLUCURONIDE; CYTOCHROME P450 1A; CYTOCHROME P450 2D6; DEFERASIROX; DEFERASIROX C 14; DEFEROXAMINE; DRUG METABOLITE; GLUCURONIDE; IRON COMPLEX; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GLUCURONIDATION; HEADACHE; HEPATOBILIARY SYSTEM; HUMAN; INTESTINE ABSORPTION; IRON OVERLOAD; LEG PAIN; MACULOPAPULAR RASH; MALE; PRIORITY JOURNAL; PRURITUS; RADIOACTIVITY; STEADY STATE;

ADULT; ANIMALS; AREA UNDER CURVE; ARYLSULFATASES; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CELLS, CULTURED; FECES; FEMALE; GLUCURONIDASE; GLUCURONIDES; HEPATOCYTES; HUMANS; HYDROXYLATION; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MOLECULAR STRUCTURE; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFURIC ACID ESTERS; TRIAZOLES; YOUNG ADULT;

EID: 77950945189     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030833     Document Type: Article

References (19)

1. Barton JC (2007) Optimal management strategies for chronic iron overload. Drugs 67:685-700.
2. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, et al. (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988.
3. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, and Waldmeier F (2008) Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36:2523-2538.
4. Bruin GJ, Waldmeier F, Boernsen KO, Pfaar U, Gross G, and Zollinger M (2006) A microplate scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: validation and applications. J Chromatogr A 1133:184-194.
5. Cui Y, König J, Buchholz JK, Spring H, Leier I, and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937.
6. Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, et al. (2008) Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol 48:428-435.
7. Hinderling PH (1997) Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49:279-295.
8. Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, et al. (2006) Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos 34:1817-1828.
9. Kushner JP, Porter JP, Olivieri NF (2001) Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001:47-61.
10. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, and Schnebli HP (2002) ICL670A: preclinical profile. Adv Exp Med Biol 509:185-203.
11. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, et al. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, doseescalation trial. Lancet 361:1597-1602.
12. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, et al. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91:873-880.
13. Rouan MC, Marfil F, Mangoni P, Séchaud R, Humbert H, and Maurer G (2001) Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biosci Sci Appl 755:203-213.
14. Séchaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, and Brun E (2008a) Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther 46:102-108.
15. Séchaud R, Robeva A, Belleli R, and Balez S (2008b) Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol 48:919-925.
16. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16.
17. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, and Vaidyanathan S (2007) Absorption, distribution, metabolism, and elimination of the direct rennin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 35:1418-1428.
18. 2 for rat, marmoset, rabbit, mouse, dog and human. Drug Metab Dispos 34:971-975.
19. Yang LP, Keam SJ, and Keating GM (2007) Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 67:2211-2230.